Herndon Capital Management’s United Therapeutics UTHR Stock Holding History

Herndon Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$12K	Hold	96	–	–	﹤0.01%	125
2017 Q1	$13K	Buy	+96	New	+$14.5K	﹤0.01%	118
2016 Q3	–	Sell	-70	Closed	-$7K	–	613
2016 Q2	$7K	Sell	70 -255	-78%	-$28.4K	﹤0.01%	209
2016 Q1	$36K	Buy	325 +317	+3,963%	+$40.1K	﹤0.01%	163
2015 Q4	$1K	Buy	+8	New	+$1.17K	﹤0.01%	198
2015 Q2	–	Sell	-116	Closed	-$19K	–	209
2015 Q1	$19K	Buy	116 +16	+16%	+$2.44K	﹤0.01%	153
2014 Q4	$13K	Sell	100 -1,123,576	-100%	-$145M	﹤0.01%	156
2014 Q3	$145M	Sell	1,123,676 -39,146	-3%	-$4.04M	1.91%	32
2014 Q2	$103M	Buy	1,162,822 +678,598	+140%	+$65.3M	1.29%	37
2014 Q1	$45.5M	Sell	484,224 -1,406,003	-74%	-$144M	0.58%	45
2013 Q4	$214M	Buy	1,890,227 +776,283	+70%	+$70M	2.7%	8
2013 Q3	$87.8M	Buy	1,113,944 +89,039	+9%	+$6.51M	1.16%	42
2013 Q2	$67.5M	Buy	+1,024,905	New	+$66M	1.01%	46

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Herndon Capital Management's UTHR Position: Q2 2017 in Review

Herndon Capital Management held its United Therapeutics (UTHR) position steady in Q2 2017 at 96 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #125.

Herndon Capital Management first reported a position in UTHR in Q2 2013 and has held it in 13 quarters since. The position peaked at $214M in Q4 2013. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Herndon Capital Management held 96 shares of United Therapeutics worth $12K as of Q2 2017.
Herndon Capital Management left its United Therapeutics share count unchanged in Q2 2017.
United Therapeutics made up ﹤0.01% of Herndon Capital Management's portfolio in Q2 2017, its #125 holding.
Herndon Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 13 quarters since.
Herndon Capital Management's United Therapeutics position peaked at $214M in Q4 2013.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Herndon Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.